CONTEXT: Angiotensin II type 1 receptor (AT(1)R) tone restricts muscle microvascular blood volume (MBV) and decreases muscle insulin delivery and glucose use. OBJECTIVE: The objective of the study was to examine whether acute AT(1)R blockade alters microvascular perfusion in skeletal and cardiac muscle in humans. SETTING: The study was conducted at the General Clinical Research Center at the University of Virginia. METHODS:Eight overnight-fasted healthy young adults were studied thrice in random order. In study 1, each subject received candesartan (32 mg) orally at time 0. In study 2, each subject received placebo at time 0 and a 1 mU/min · kg euglycemic insulin clamp from time 240 to 360 min. In study 3, each subject received candesartan (32 mg) orally at time 0 and insulin infusion from 240 to 360 min. Forearm skeletal and cardiac muscle MBV, microvascular flow velocity, and microvascular blood flow (MBF) were determined at baseline and at 240 and 360 min. RESULTS:Candesartan treatment acutely recruited microvasculature in both skeletal and cardiac muscle by significantly increasing MBV (P < 0.03 and P = 0.02, respectively) and MBF (P < 0.03 for both) without altering microvascular flow velocity. Insulin infusion significantly increased cardiac MBV (P = 0.02) and MBF (P < 0.02). Superimposing insulin infusion 4 h after candesartan ingestion did not further recruit microvasculature. Insulin-mediated whole-body glucose disposal did not differ with or without candesartan pretreatment. CONCLUSIONS: Acute AT(1)R blockade with candesartan recruits skeletal as well as cardiac muscle microvasculature in healthy humans without altering insulin-mediated whole-body glucose disposal. This may contribute to the observed improvement in the cardiovascular outcomes in patients receiving prolonged treatment with AT(1)R blockers.
RCT Entities:
CONTEXT: Angiotensin II type 1 receptor (AT(1)R) tone restricts muscle microvascular blood volume (MBV) and decreases muscle insulin delivery and glucose use. OBJECTIVE: The objective of the study was to examine whether acute AT(1)R blockade alters microvascular perfusion in skeletal and cardiac muscle in humans. SETTING: The study was conducted at the General Clinical Research Center at the University of Virginia. METHODS: Eight overnight-fasted healthy young adults were studied thrice in random order. In study 1, each subject received candesartan (32 mg) orally at time 0. In study 2, each subject received placebo at time 0 and a 1 mU/min · kg euglycemic insulin clamp from time 240 to 360 min. In study 3, each subject received candesartan (32 mg) orally at time 0 and insulin infusion from 240 to 360 min. Forearm skeletal and cardiac muscle MBV, microvascular flow velocity, and microvascular blood flow (MBF) were determined at baseline and at 240 and 360 min. RESULTS:Candesartan treatment acutely recruited microvasculature in both skeletal and cardiac muscle by significantly increasing MBV (P < 0.03 and P = 0.02, respectively) and MBF (P < 0.03 for both) without altering microvascular flow velocity. Insulin infusion significantly increased cardiac MBV (P = 0.02) and MBF (P < 0.02). Superimposing insulin infusion 4 h after candesartan ingestion did not further recruit microvasculature. Insulin-mediated whole-body glucose disposal did not differ with or without candesartan pretreatment. CONCLUSIONS: Acute AT(1)R blockade with candesartan recruits skeletal as well as cardiac muscle microvasculature in healthy humans without altering insulin-mediated whole-body glucose disposal. This may contribute to the observed improvement in the cardiovascular outcomes in patients receiving prolonged treatment with AT(1)R blockers.
Authors: Wendy W Batenburg; Ingrid M Garrelds; Catherine Chapuis Bernasconi; Lucienne Juillerat-Jeanneret; Jorge P van Kats; Pramod R Saxena; A H Jan Danser Journal: Circulation Date: 2004-04-26 Impact factor: 29.690
Authors: T A Buchanan; H Thawani; W Kades; J G Modrall; F A Weaver; C Laurel; R Poppiti; A Xiang; W Hsueh Journal: J Clin Invest Date: 1993-08 Impact factor: 14.808
Authors: Lucy H Clerk; Michelle A Vincent; Eugene J Barrett; Miles F Lankford; Jonathan R Lindner Journal: Am J Physiol Endocrinol Metab Date: 2007-10-02 Impact factor: 4.310
Authors: Fei Yan; Zhaoshun Yuan; Nasui Wang; Robert M Carey; Kevin W Aylor; Li Chen; Xinmin Zhou; Zhenqi Liu Journal: Endocrinology Date: 2018-02-01 Impact factor: 4.736
Authors: Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; Kevin W Aylor; Ananda Basu; Zhenqi Liu Journal: Clin Sci (Lond) Date: 2014-08 Impact factor: 6.124
Authors: Nasui Wang; Alvin W K Tan; Linda A Jahn; Lee Hartline; James T Patrie; Shaoda Lin; Eugene J Barrett; Kevin W Aylor; Zhenqi Liu Journal: Diabetes Care Date: 2019-12-30 Impact factor: 19.112
Authors: Alvin W K Tan; Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; James T Patrie; Kevin W Aylor; Ananda Basu; Zhenqi Liu Journal: J Endocr Soc Date: 2018-01-22